Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 3
2008 4
2009 1
2010 1
2011 1
2012 1
2013 2
2014 2
2015 1
2016 1
2017 1
2018 4
2019 4
2020 3
2021 2
2022 5
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab for the treatment of esophageal cancer.
Yamamoto S, Kato K. Yamamoto S, et al. Expert Opin Biol Ther. 2020 Oct;20(10):1143-1150. doi: 10.1080/14712598.2020.1792881. Epub 2020 Jul 14. Expert Opin Biol Ther. 2020. PMID: 32620063 Review.
AREA COVERED: In this review, we provide an overview of pembrolizumab as a compound and present the available clinical data related to EC treatment. EXPERT OPINION: In our opinion, pembrolizumab is one of the standard treatment agents for second-line metastatic or recur …
AREA COVERED: In this review, we provide an overview of pembrolizumab as a compound and present the available clinical data related t …
Significance of chemotherapy-free interval and tumor regression grade in patients with recurrent esophageal squamous cell carcinoma receiving chemotherapy with fluorouracil and platinum after esophagectomy following preoperative chemotherapy.
Okunaka M, Kotani D, Demachi K, Fujiwara H, Sakashita S, Yoshino T, Fujita T, Kojima T. Okunaka M, et al. Esophagus. 2022 Apr;19(2):240-249. doi: 10.1007/s10388-021-00885-3. Epub 2021 Oct 5. Esophagus. 2022. PMID: 34611830 Free PMC article.
Clinical outcomes of surgical resection for recurrent lesion after curative esophagectomy for esophageal squamous cell carcinoma: a nationwide, large-scale retrospective study.
Kudou K, Saeki H, Nakashima Y, Kimura Y, Oki E, Mori M, Shimokawa M, Kakeji Y, Toh Y, Doki Y, Matsubara H. Kudou K, et al. Esophagus. 2022 Jan;19(1):57-68. doi: 10.1007/s10388-021-00878-2. Epub 2021 Sep 12. Esophagus. 2022. PMID: 34510325 Free PMC article.
According to multivariate analyses, pN 0-1 (P = 0.0146), lung metastasis (P = 0.0274), recurrence-free interval after curative esophagectomy of 550 days (P = 0.0266), R0 resection (P = 0.0009), and absence of severe complications after resection for recurrent lesions (Clavien-Din …
According to multivariate analyses, pN 0-1 (P = 0.0146), lung metastasis (P = 0.0274), recurrence-free interval after curative esophagectomy …
Inflammatory prognostic factors in advanced or recurrent esophageal squamous cell carcinoma treated with nivolumab.
Ikoma T, Shimokawa M, Matsumoto T, Boku S, Yasuda T, Shibata N, Kurioka Y, Takatani M, Nobuhisa T, Namikawa T, Kitagawa H, Hanazaki K, Doi K, Shimada T, Tsumura T, Marusawa H, Kanaya S, Morita S, Inokuma T, Nagai H, Yasui H, Satake H. Ikoma T, et al. Cancer Immunol Immunother. 2023 Feb;72(2):427-435. doi: 10.1007/s00262-022-03265-7. Epub 2022 Aug 4. Cancer Immunol Immunother. 2023. PMID: 35927359 Free PMC article.
BACKGROUND: In Japan, nivolumab administration is the standard treatment for patients with unresectable advanced or recurrent esophageal squamous cell carcinoma (ESCC) who are refractory or intolerant to fluoropyrimidines and platinum-based chem …
BACKGROUND: In Japan, nivolumab administration is the standard treatment for patients with unresectable advanced or recurrent esop …
Long-term survival after definitive proton beam therapy for oligorecurrent esophageal squamous cell carcinoma: a case report.
Ishikawa Y, Suzuki M, Yamaguchi H, Seto I, Machida M, Takagawa Y, Jingu K, Kikuchi Y, Murakami M. Ishikawa Y, et al. J Med Case Rep. 2022 Feb 14;16(1):68. doi: 10.1186/s13256-022-03275-0. J Med Case Rep. 2022. PMID: 35152904 Free PMC article.
BACKGROUND: Radical esophagectomy for esophageal squamous cell carcinoma has improved survival, but the rate of recurrence is high. Patients of recurrent esophageal squamous cell carcinoma after failure of chemotherapy have a poor prognosis. ...
BACKGROUND: Radical esophagectomy for esophageal squamous cell carcinoma has improved survival, but the rate of recurrence is high. Patients …
Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy.
Chen WW, Lin CC, Huang TC, Cheng AL, Yeh KH, Hsu CH. Chen WW, et al. Anticancer Res. 2013 Sep;33(9):4123-8. Anticancer Res. 2013. PMID: 24023359
CONCLUSION: The identification of prognostic factors could facilitate for future design of randomized studies on the efficacy of three-drug combinations for metastatic ESCC....
CONCLUSION: The identification of prognostic factors could facilitate for future design of randomized studies on the efficacy of thre …
Timing of the infusion of nivolumab for patients with recurrent or metastatic squamous cell carcinoma of the esophagus influences its efficacy.
Nomura M, Hosokai T, Tamaoki M, Yokoyama A, Matsumoto S, Muto M. Nomura M, et al. Esophagus. 2023 Oct;20(4):722-731. doi: 10.1007/s10388-023-01006-y. Epub 2023 Apr 24. Esophagus. 2023. PMID: 37093536 Free PMC article.
The objective of this study was to clarify whether time-of-day patterns (early or late in the daytime) of the infusion of nivolumab and whether its duration affect treatment efficacy in metastatic or recurrent esophageal squamous cell carcinoma …
The objective of this study was to clarify whether time-of-day patterns (early or late in the daytime) of the infusion of nivolumab and whet …
A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy.
Nakajima Y, Kawada K, Tokairin Y, Hoshino A, Okada T, Kawano T. Nakajima Y, et al. Dig Surg. 2018;35(2):131-137. doi: 10.1159/000477265. Epub 2017 May 30. Dig Surg. 2018. PMID: 28554183
BACKGROUND/AIMS: This study documents the clinical efficacy and toxicity of S-1 and paclitaxel (S1/PTX) in patients with unresectable or postoperative recurrent esophageal squamous cell carcinoma (ESCC) who had been previously treated wit …
BACKGROUND/AIMS: This study documents the clinical efficacy and toxicity of S-1 and paclitaxel (S1/PTX) in patients with unresectable …
Weekly Chemotherapy of 5-Fluorouracil plus Cisplatin Concurrent with Radiotherapy for Esophageal Squamous Cell Carcinoma Patients with Postoperative Locoregional Recurrence: Results from a Phase II Study.
Chen B, Li Q, Li Q, Qiu B, Xi M, Liu M, Hu Y, Zhu Y. Chen B, et al. Oncologist. 2020 Apr;25(4):308-e625. doi: 10.1634/theoncologist.2019-0931. Epub 2019 Dec 27. Oncologist. 2020. PMID: 31880371 Free PMC article. Clinical Trial.
LESSONS LEARNED: Weekly treatment with 5-fluorouracil and cisplatin, concurrent with radiotherapy, achieved promising response rates in patients with postoperative recurrent esophageal squamous cell carcinoma. Superior toxicity results were also …
LESSONS LEARNED: Weekly treatment with 5-fluorouracil and cisplatin, concurrent with radiotherapy, achieved promising response rates in pati …
29 results